1520 results about "Metabolic disease" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof. Particularly, the present invention relates to a compound represented by general formula (XIX), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description.

The invention relates to a phenyl-containing heterocyclic derivative regulator as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (XVI), a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, each substituent in the general formula (XVI) being as defined in the specification # imgabs0 #

Most disease-associated genetic loci map to more than one disease or trait, suggesting they act through multiple cell types and tissues giving rise to complex disease phenotypes. This pervasive pleiotropy of human diseases presents a tremendous burden on identifying mediating mechanisms and therapeutic targets. Multiple metabolic risk haplotypes are associated with risk for metabolic diseases. However, whether a haplotype actually causes a disease and the mechanisms that cause the disease are unknown. Integration of phenotypic and transcriptional profiling in primary human cells allows for functional characterization of disease-associated genetic variants. Applicants have analyzed multiple risk haplotypes and determined the function of risk haplotypes involved in causation of specific metabolic phenotypes, such as type 2 diabetes and lipodystrophy. Methods of treatments are disclosed herein.

The invention relates to an exercise prescription recommendation method and device, electronic equipment and a storage medium. The exercise prescription recommendation method comprises the following steps: constructing multiple agents at least integrated with a user agent, a doctor agent, a nutritionist agent and an exercise health agent, and providing an interactive interface to realize information sharing, competition or negotiation and decision and scheme generation between every two agents; pre-training is carried out based on the professional domain knowledge maps corresponding to the different agents, so that a multi-agent exercise prescription recommendation model is obtained; and inputting the obtained various related conditions of the metabolic disease patient into the exercise prescription recommendation model for reasoning to obtain a target exercise prescription. According to the invention, accurate and personalized exercise prescriptions can be formulated for patients with metabolic diseases.

The invention provides a risk prediction method and system for cardiovascular and metabolic diseases. The method comprises the following steps: collecting continuous cardiovascular-metabolism time sequence data, and extracting phase delay parameters to construct a lipid transport rhythm out-of-synchronization characteristic spectrum; quantifying the topological connection strength of the gene cluster based on the three-dimensional genome interaction strength matrix, and generating a genetic prediction model; a vascular endothelial metabolism buffer attenuation trajectory is calculated through simulation, and a critical environment exposure parameter is determined by matching a genetic instability threshold value; and fusing multi-source data to construct a dynamic toughness model, calculating a phase space shrinkage rate of a vascular metabolism steady-state boundary, and triggering graded early warning. According to the technical scheme provided by the invention, ultra-early warning of cardiovascular metabolism risks is realized, and the individual intervention target spot recognition precision is improved.

The invention relates to a nitrogen-containing heteroaromatic ring derivative regulator as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, each substituent in the general formula (I) being as defined in the specification. # imgabs0 #

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

The invention relates to the technical field of health management of old people, and discloses a method and a system for predicting multiple diseases of old people. The method comprises the following steps: acquiring multi-modal health monitoring data of a target old person in a preset time period, wherein the multi-modal health monitoring data comprises physiological index time sequence data, a medication record sequence and a daily activity ability evaluation result; and performing cross-modal correlation analysis on the multi-modal health monitoring data to generate a disease interaction characteristic matrix containing metabolic disease correlation degree, circulatory system disease coordination index and neurodegenerative disease progress rate. And performing hierarchical clustering processing on the feature matrix by adopting a dynamic weight distribution algorithm, and outputting potential common disease combinations of the target old people and a priority score of each common disease combination. And generating a personalized intervention strategy set including a drug interaction avoidance scheme, a rehabilitation training intensity adjustment scheme and a nutrition intake ratio scheme according to the priority score.

The invention belongs to the field of medical chemistry, and particularly discloses a protein tyrosine phosphatase inhibitor, a pharmaceutical composition and application of the protein tyrosine phosphatase inhibitor, and the protein tyrosine phosphatase inhibitor is a compound shown in a general formula (I) or pharmaceutically acceptable salt of the compound. The invention also discloses a method for using the protein tyrosine phosphatase inhibitor to treat cancers, metabolic diseases and other related diseases. # imgabs0 #

The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.

Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 consecutive nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 consecutive nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.

The present invention relates to novel compounds of formulae (I) and (III), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN 1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

The invention relates to an application of a bifidobacterium animalis subsp. Lactis BGI-N3 (the preservation number is CCTCC (China Center For Type Culture Collection) NO: M20221585) or a composition containing the bifidobacterium animalis subsp. Lactis BGI-N3 as an active ingredient in the preparation of a product for preventing and / or treating metabolic diseases, and particularly relates to an application of the bifidobacterium animalis subsp. Lactis BGI-N3 or a composition containing the bifidobacterium animalis subsp. Lactis BGI-N3 as an active ingredient in the preparation of a product for preventing and / or treating metabolic diseases. The bifidobacterium animalis subsp. Lactis comprises a 16S rDNA (ribosomal deoxyribonucleic acid) sequence as shown in SEQ ID NO: 1. The animal bifidobacterium subsp. Lactis BGI-N3 provided by the embodiment of the invention has good safety and excellent gastrointestinal tract environment tolerance, and can effectively reduce the food calorie conversion rate, regulate the systemic chronic inflammation level and improve the fat accumulation condition so as to prevent and / or treat metabolic diseases, such as obesity.

A GLP-1-Fc-FGF21 double-target fusion protein composition and the use thereof. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by means of adding the buffer solution, the generation of visible particles can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein is improved, so that the shelf life of a product can be prolonged. The composition can be used for treating and / or preventing metabolic diseases, such as diabetes, hyperlipidemia, obesity and diseases related to fatty liver.

Provided is the use of a conjugated cholic acid, tryptophan-conjugated bile acids (TrpCA) or a TrpCA-producing strain for preventing and / or treating a metabolic disease. The present disclosure relates to the use of tryptophan-conjugated cholic acid or its producing bacteria strain in the preparation of a composition for preventing and / or treating a metabolic disease, or for promoting GLP-1 and / or insulin production. The inventors have discovered for the first time that the tryptophan-conjugated cholic acid can significantly promote the secretion of GLP-1 in both in vivo animal model and in vitro cell model, thereby reducing weight, lowering blood glucose and relieving symptoms of non-alcoholic fatty liver disease. Moreover, colonization of the selected probiotics can also have the same metabolic improvement effects.

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions that respond favorably to PTPN1 or PTPN2 inhibitor treatment, such as cancer or metabolic diseases.

There is provided the use of Lactobacillus paracasei or a afterbiogen in the preparation of a pharmaceutical composition or a food composition for the production of tryptophan-binding cholic acid. The Lactobacillus paracasei or the afterbiogen thereof can be used to prevent and / or treat metabolic diseases or to promote the production of GLP-1 and / or insulin, or to maintain blood glucose healthy levels, to maintain blood lipid health and / or to control fat in the body.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention provides application of combined cholic acid TrpCA and producing bacteria thereof in treating and preventing metabolic diseases. The present invention relates to the use of tryptophan-binding cholic acid or a producing bacterium thereof in the preparation of a composition for preventing and / or treating a metabolic disease or for promoting the production of GLP-1 and / or insulin. The inventor finds for the first time that tryptophan-bound cholic acid can remarkably promote secretion of GLP-1 on an in-vivo animal model and an in-vitro cell model, the effects of reducing weight, reducing blood sugar and relieving the symptoms of the non-alcoholic fatty liver disease are achieved, and the same metabolism improvement effect can also be achieved through planting of probiotics capable of generating cholic acid TrpCA.

The present invention relates to an optimized polynucleotide encoding a brain-derived neurotrophic factor (BDNF), a transgenic expression cassette comprising the polynucleotide, a recombinant vector, and a medicament useful for the prevention or treatment of neurodegenerative diseases, neurodevelopment-related diseases, stroke, chronic pain, nerve injury, mental disorders, and / or metabolic diseases. The polynucleotide disclosed by the invention can efficiently express the BDNF through codon optimization, and particularly, the expression quantity of the BDNF in nerve cells is remarkably improved.

The present invention relates to a compound having a structure represented by formula (I) and having GLP-1 receptor agonistic activity; and the use of said compound and a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof in the preparation of a GLP-1 receptor agonist and in the preparation of a drug for treating and / or preventing metabolic diseases.

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

Provided herein are compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the sequence of SEQ ID NO: 35, and the compounds have an anion:cation molar ratio of from about 1:1 to about 1:7, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.

Provided herein are degrader compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 degrader treatment, e.g., a cancer or a metabolic disease.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

Provided here is use of Lacticaseibacillus paracasei or postbiotics thereof for the manufacture of a pharmaceutical or a food composition for generating a cholic acid conjugated to tryptophan. The Lacticaseibacillus paracasei or the postbiotics thereof can be used for preventing and / or treating a metabolic disease, or for promoting GLP-1 and / or insulin production, or for maintaining healthy blood glucose level, maintaining healthy lipid level and / or controlling body fat.

The invention provides a polyphenolic composition and method for its use and manufacture in the treatment of metabolic disorders. The active agents of the composition can include flavonoids and anthocyanins. The active agents can be obtained from rose petal extract, including Rosa multiflora rose petal extract. The composition finds use in the treatment of obesity and complications associated with obesity.

The present disclosure provides isolated Lactobacillus crispatus, a composition comprising the same, and uses thereof, which can be used to treat, prevent, alleviate or alleviate liver and kidney diseases, metabolic diseases, and the like.